A.B.JAK2 Mutation in Health Control Group Threshold Analysis

Jan 13, 2025

10 likes | 77 Views

This supplemental figure presents the analysis of A.B.JAK2 mutation prevalence in a health control group, utilizing a 33% cutoff threshold. The data provides valuable insights into the distribution of this mutation among healthy individuals.

Share Presentation

Embed Code

Link

abjak2 mutation
health control group
prevalence analysis
mutation distribution

javen

Download Presentation

A.B.JAK2 Mutation in Health Control Group Threshold Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 1 Purandare et al. A B JAK2 0 Percent Control Cut-Off 33 Percent Control Cut-Off

Lim et al, Supplemental Figure S1.

Lim et al, Supplemental Figure S1. . a/b. a. a. b/c. a/b. c/d. c/d. c/d. d. e. Arsenic. Plant height (Cm). f. g. [mg/Kg]. 1.5. 5.0. 7.0. 0. 10. 50. 100. 150. 0. 200. 300. 400. 500. 0. As[ μ M]. Cadmium. a/b. a. b. b. c. c. d. d. d/e. e. f. g.

173 views • 5 slides

Patel et al Supplemental Figure S4

A . Patel et al Supplemental Figure S4. 4.1 ± 1.9. SK-ES-1. 13.0 ± 3.8. SK- N-MC. 0. 4. 12. RASSF1A Fold Induction with 5-AZA treatment. B . 39.5 ± 14.5. SK-ES-1. 185.5 ± 45.6. SK- N-MC. 24.3 ± 5.9. A673. 0. 100. 150. 200. 50. CALCA Fold Induction with 5-AZA treatment.

109 views • 1 slides

Supplemental Figure 3. Kiem et al.

1500. 600. 300. 200. 100. 1500. 600. 300. 200. 100. Supplemental Figure 3. Kiem et al. a. Copy Number in Foamy Transduced Lymphocytes. 3. 2. Copy Number. 1. 0. FV-SMPGW. FV-UsI-SMPGW. FV-HsI-SMPGW. FV-SC46-IMPGW. FV-UsI-SC46-IMPGW. FV-UsIIUsIUR5-SMPGW. FV-HsIIHsIHR5-SMPGW.

93 views • 1 slides

Zang, et al. Supplemental Figure 2

Zang, et al. Supplemental Figure 2. Non-diabetic Diabetic Diabetic+S17834.

107 views • 1 slides

Yoon et al. Supplemental Figure S1

Yoon et al. Supplemental Figure S1. A. B. AGS. MKN-45. N87. CFPAC-1. PANC-1. AGS. MKN-45. N87. CFPAC-1. PANC-1. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Spheroid. Spheroid. Spheroid. Spheroid.

127 views • 1 slides

Supplemental Figure Fung et al.

Supplemental Figure Fung et al. A. B. Fluorescence and phase-contrast microscopic images showing ( A ) co-culture of MS5-GFP cells with human primary macrophages (including those encircled red). Note stellate network of MS5 cells (white arrows) spanning across an

147 views • 1 slides

Lim et al, Supplemental Figure S1.

Lim et al, Supplemental Figure S1. OsRING-H2 type : 4 OsRING-HC type : 6 OsRING-v type : 2. OsRING-H2 type : 5 OsRING-HC type : 1 OsRING-v type : 1. OsRING-H2 type : 9 OsRING-HC type : 8 OsRING-v type : 2. OsRING-H2 type : 9 OsRING-HC type : 8 OsRING-v type : 2.

221 views • 14 slides

Yoon et al. Supplemental Figure S3

Yoon et al. Supplemental Figure S3. A. AGS MKN-45 N87. Vismodegib. B. 5-fluoruracil. DMSO. Vismodegib. 5-fluoruracil. Cisplatin. Cisplatin. AGS Spheroid. MKN-45 Spheroid. N87 Spheroid.

147 views • 1 slides

Weaver et al. supplemental Figure 1

Weaver et al. supplemental Figure 1. A BALB/c. Epitope. Immunogen. Peptide. B1. B2. B3. B4. B5. B6. B7. B8. B9. B10. B11. B12. UG37(A). KVTFEPIPIHYCAPA (53). STVQCTHGIRPVVST (62). RIKQIINMWQRVGQA (104). GIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQ (136,137,138,140).

123 views • 3 slides

Geng et al. Supplemental Figure 1

Geng et al. Supplemental Figure 1. murine 3B11 tumor vascular endothelial cells. Human micro-vascular endothelial cells. Analog II. DMSO. Geng et al Supplemental Figure 2. Geng et al Supplemental Figure 3. Geng et al Supplemental Figure 4. Geng et al Supplemental Figure 5.

215 views • 6 slides

Tsutsumi et al., Supplemental Figure 1

80. 40. 80. 60. 0. 40. 10 0. 10 1. 10 2. 10 3. 20. Negative control. GA-FITC. GA-FITC + DMAG-N-oxide. 0. 10 0. 10 1. 10 2. 10 3. Negative control. mock. DMAG-N-oxide. Tsutsumi et al., Supplemental Figure 1. a. Cell Number (%). Fluorescence Intensity (log). b.

82 views • 1 slides

Bush, et al., Supplemental Figure S3.

Bush, et al., Supplemental Figure S3. B. A. C. WT 1. WT1 -- Normal Karyotype. DAPI. KO2 Endoreduplication. Mean = 1.4%. p value = 0.001. KO1 -- 39, XX, -4, chtb(1), chtb(11), chtb(12). KO 2. DAPI. Mean = 4.4%. E. D.

109 views • 1 slides

Supplemental Figure 1 Narainsamy et al.

Supplemental Figure 1 Narainsamy et al. A. B. Supplemental Figure 2 Narainsamy et al. A. B. 3276. 1375. 757. 1438. Supplemental Figure 3 Narainsamy et al. B. Positive ion mode. Negative ion mode. <10. 10-25. 25-35. 35-50. >50. <10. 10-25. 25-35. 35-50. >50. CV (%).

161 views • 7 slides

Kraenzlin et al. Supplemental Figure 1

µV. 2.0e+5. PYD. 1.5e+5. ISTD. Fluorescence (295/400 nm). 1.0e+5. DPD. 0.5e+4. 0.0. -0.5e+4. 2. 4. 6. 8. 10. 12. Time (min). Kraenzlin et al. Supplemental Figure 1. Supplemental Figure 1:

104 views • 1 slides

JH Neltner et al, Supplemental Figure 1

JH Neltner et al, Supplemental Figure 1. Gray matter (green boxes). White matter (yellow boxes). JH Neltner et al, Supplemental Figure 2. A. B. CD 31 CD 34 Collagen IV SMA Factor VIII. C. D. E. F. G. H. I. J.

135 views • 2 slides

Vernin et al., supplemental Figure 5

PI positive cells (%). Vernin et al., supplemental Figure 5.

114 views • 1 slides

Supplemental Figure 1, Ghielmetti et al

Supplemental Figure 1, Ghielmetti et al.

103 views • 1 slides

Supplemental Figure 3, Ghielmetti et al

medium. TB40/E. TB40/E-UV. Supplemental Figure 3, Ghielmetti et al.

113 views • 1 slides

Supplemental Figure 1 Geffroy et al.

CNL-B19. CNL-BA8. l B35. CNL-BA11. l B29. CNL-J11. l J9. Supplemental Figure 1 Geffroy et al. BAT93. JaloEEP558. Genetic position 1. Genetic position 1. 10Kb. CNL-J8. l J39. CNL-JA78. l J107. CNL-J9. l J15. Genetic position 2. CNL-B16. CNL-B17. l B10. Genetic position 3.

117 views • 1 slides

Kiem et al., Supplemental Figure 1

Kiem et al., Supplemental Figure 1. Relative luciferase expression. control. human CCR5-741. human CCR5-1024. macaque CCR5-741. macaque CCR5-1024.

100 views • 1 slides

Glazov et al., Supplemental Figure 6

Glazov et al., Supplemental Figure 6.

133 views • 1 slides

Frietze et al. Supplemental Figure 1

Frietze et al. Supplemental Figure 1.

69 views • 1 slides

More Related